- Record: found
- Abstract: not found
- Article: not found
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato ,
Byoung Chul Cho ,
Masanobu Takahashi ,
Morihito Okada ,
Chen-Yuan Lin ,
Keisho Chin ,
Shigenori Kadowaki ,
Myung-Ju Ahn ,
Yasuo Hamamoto ,
Yuichiro Doki ,
Chueh-Chuan Yen ,
Yutaro Kubota ,
Sung-Bae Kim ,
Chih-Hung Hsu ,
Eva Holtved ,
Ioannis Xynos ,
Mamoru Kodani ,
Yuko Kitagawa
September 2019
September 2019
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Chemotherapy for patients with advanced oesophageal squamous cell carcinoma offers
poor long-term survival prospects. We report the final analysis from our study of
the immune checkpoint PD-1 inhibitor nivolumab versus chemotherapy in patients with
previously treated advanced oesophageal squamous cell carcinoma.